8-K current report · filed Nov 4, 2026

VIEMED HEALTHCARE, INC. (VMD) 8-K Current Report: November 4, 2026

Item 2.02Item 7.01Item EX-99.3Item EX-99.1Item EX-99.2VMD overview

Short answer

VIEMED HEALTHCARE, INC. (VMD) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 and nine-month fiscal 2026 results announced for periods ended September 30, 2026.

VIEMED HEALTHCARE, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 and nine-month fiscal 2026 results announced for periods ended September 30, 2026
  • Financial Supplement provides additional operating and financial detail for investor analysis
  • Results and supplement attached as Exhibits 99.1 and 99.2

Item 7.01 · Regulation FD Disclosure

  • Investor deck published as Exhibit 99.3 and available on Viemed’s investor website
  • Presentation intended for investor and analyst meetings, signaling updated corporate messaging
  • Deck should be reviewed for management’s strategic priorities, operating metrics and financial outlook

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue reached a record $80.7M, up 12.2% year over year and 3.3% sequentially, confirming diversified growth momentum
  • Net income attributable to Viemed rose 32.0% year over year to $4.6M, while diluted EPS increased to $0.11
  • Adjusted EBITDA grew 24.4% sequentially to $17.1M, with margin expanding to 21.1% from 17.6%
  • PAP therapy patients rose 37.5% year over year to 43,861, supporting less capital-intensive growth beyond ventilator rentals
  • 2026 guidance improved: revenue floor raised to $316M, Adjusted EBITDA narrowed to $64M-$66M, and net CAPEX reduced to 8.0%-9.0% of revenue

Item EX-99.2 · Exhibit EX-99.2

  • Record Q3 revenue $80.7M, up 12.2% YoY and 3.3% sequentially, confirming continued platform expansion
  • Net income $4.6M, up 32.0% YoY, with diluted EPS $0.11 and margin improving to 5.7%
  • Adjusted EBITDA $17.1M, up 24.4% sequentially, lifting margin to 21.1% from 17.6%
  • PAP patients reached 43,861, up 37.5% YoY, while sleep resupply patients reached 40,918, up 22.1%
  • Full-year guidance narrowed to revenue $316M-$320M and Adjusted EBITDA $64M-$66M, with net CAPEX reduced to 8.0%-9.0% of revenue

Item EX-99.3 · Exhibit EX-99.3

  • 2026 guidance: net revenue $316M-$320M and Adjusted EBITDA $64M-$66M, signaling continued double-digit growth
  • Q3 2026 revenue $80.7M, up 12% YoY, with ventilator rental revenue up 7.4% to $37.5M
  • Sleep remains the key growth engine: PAP patients up 38% and resupply patients up 22% YoY
  • New repurchase authorization up to 5% of shares outstanding, with 795,802 shares already repurchased at $9.47 average
  • Financial flexibility supports acquisitions and buybacks: $0M net debt and $46M available credit as of September 30, 2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other VIEMED HEALTHCARE, INC. 8-K filings

Get the next VMD 8-K as it lands

Follow VMD for push alerts, or ask the research agent what this filing means.